These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 2971273)

  • 21. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys.
    Bergman J; Spealman RD; Madras BK; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 1996 Mar; 276(3):942-50. PubMed ID: 8786574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D; Osborn CV
    Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of D1- and D2-dopamine agonists on neocortical and hippocampal EEG activity of rat brain: modulation of rimcazole effect.
    Verma A; Kulkarni SK; Nayar U
    Methods Find Exp Clin Pharmacol; 1993 Oct; 15(8):515-25. PubMed ID: 7905945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Brain dopamine receptors. Interactions between D1 and D2 receptors, and dopamine mediated behaviour].
    Costentin J
    Therapie; 1991; 46(4):269-82. PubMed ID: 1683022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of dopaminergic systems in opioid receptor desensitization in nucleus accumbens and caudate putamen of rat after chronic morphine treatment.
    Noble F; Cox BM
    J Pharmacol Exp Ther; 1997 Nov; 283(2):557-65. PubMed ID: 9353370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine-D1 and -D2 receptors differentially regulate synapsin II expression in the rat brain.
    Chong VZ; Skoblenick K; Morin F; Xu Y; Mishra RK
    Neuroscience; 2006; 138(2):587-99. PubMed ID: 16413126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
    Ralph RJ; Caine SB
    J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. D-1 and D-2 dopamine receptor blockade: interactive effects in vitro and in vivo.
    Saller CF; Salama AI
    J Pharmacol Exp Ther; 1986 Mar; 236(3):714-20. PubMed ID: 3005552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electrophysiological verification of the presence of D1 and D2 dopamine receptors within the ventral pallidum.
    Napier TC; Maslowski-Cobuzzi RJ
    Synapse; 1994 Jul; 17(3):160-6. PubMed ID: 7974198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B-HT 920 stimulates postsynaptic D2 dopamine receptors in the normal rat: electrophysiological and behavioral evidence.
    Johansen PA; Clarkl D; White FJ
    Life Sci; 1988; 43(6):515-24. PubMed ID: 2900459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine receptor activation in bovine pinealocyte via a cAMP-dependent transcription pathway.
    Santanavanich C; Ebadi M; Govitrapong P
    J Pineal Res; 2005 Apr; 38(3):170-5. PubMed ID: 15725338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects.
    Walters JR; Bergstrom DA; Carlson JH; Chase TN; Braun AR
    Science; 1987 May; 236(4802):719-22. PubMed ID: 2953072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral differentiation between effects elicited at dopamine D-1 and D-2 receptors in rats with normosensitive DA receptors.
    Arnt J; Hyttel J
    Pharmacopsychiatry; 1988 Jan; 21(1):24-7. PubMed ID: 2966410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic interactions of D1- and D2-selective dopamine agonists in animal models for Parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias.
    Robertson HA
    Can J Neurol Sci; 1992 Feb; 19(1 Suppl):147-52. PubMed ID: 1349263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism.
    Piomelli D; Pilon C; Giros B; Sokoloff P; Martres MP; Schwartz JC
    Nature; 1991 Sep; 353(6340):164-7. PubMed ID: 1909771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. D-1/D-2 dopamine receptor interactions in the regulation of extrapyramidal motor function: studies in animal models and parkinsonian patients.
    Barone P; Braun AR; Chase TN
    Clin Neuropharmacol; 1986; 9 Suppl 4():128-30. PubMed ID: 2952266
    [No Abstract]   [Full Text] [Related]  

  • 40. Modulation of in vivo dopamine release by D2 but not D1 receptor agonists and antagonists.
    Boyar WC; Altar CA
    J Neurochem; 1987 Mar; 48(3):824-31. PubMed ID: 2949060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.